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therapy (p = 0.003) as compared to non-depressed patients.
Results of an extended-Cox proportional hazard model indicated
that the hazard to switch/augment therapy was 2.4 times more
for depressed patients as compared to non-depressed patients 
in the latter six-months of the follow-up period (p = 0.0005).
Depression was consistently found to be a signiﬁcant predictor
of adherence, with depressed patients being 3–6% less adherent
to their OHAs than non-depressed patients. CONCLUSION:
Depression signiﬁcantly impacts utilization patterns and adher-
ence to OHAs in patients with type-2 diabetes. This lack of
adherence may affect glycemic control and consequently inci-
dence of diabetes related complications. The study results imply
that depression screening and treatment may be included in the
protocol for management of type-2 diabetes patients.
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OBJECTIVE: Measure the effect of non-adherence to oral antidi-
abetic medications on total and diabetes-attributable health care
costs in a managed care population. METHODS: Using a large
managed care administrative claims database, all patients with a
prescription for an oral antidiabetic from January, 2000 through
June, 2001 were selected (n = 54,505) from among continuously
eligible patients age 18 years and older. Total and diabetes-
attributable costs were computed during one year of follow-up.
A non-adherence variable, the total number of days that each
patient was without antidiabetic medication, was computed. The
computation allowed for stashing of antidiabetics within classes
but not across classes (alpha-glucosidase, metformin, other 
secretagogues, sulfonylureas, thiazolidinediones). Multivariate
log-linear regressions were estimated for costs using adherence,
diabetes severity, overall comorbidity burden, hospitalization in
prior six-months, concomitant insulin use, patient initiating
antidiabetic therapy, insurance plan, and demographic variables.
RESULTS: Overall, total and diabetes-attributable costs
decreased with worsened adherence to oral antidiabetics.
However, for the most costly patients (top 40%, median annual
costs of $9391), there was a 1.66% increase in total costs for
each 30 additional days without oral medication. Only patients
with the top 10% of attributable costs had increased diabetes-
attributable costs with worsening adherence. After excluding the
cost of prescription antidiabetic medications, non-adherence
increased costs in all but the lowest-cost patients (bottom 30%).
The top 40%, with median non-drug attributable costs of $1339,
realized a 6.38% cost increase with each 30 days without med-
ication and the middle 30%, with median of $741, realized a
3.76% increase. CONCLUSIONS: During one year of follow-
up, non-adherence to oral antidiabetics increased total and dia-
betes-attributable costs for the most resource-intensive patients
but did not increase average costs for the population overall. For
the 70% of patients with the highest diabetes-attributable costs,
worsening adherence increased the medical services portion of
diabetes-attributable costs.
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OBJECTIVES: This study aims to evaluate medication adher-
ence, utilization and costs associated with American Pharmacist
Association’s (AphA) Diabetes Care Project. METHODS:
Patients with diabetes were assigned to an intervention or control
cohort based on enrollment in APhA’s Diabetes Care Project.
Individual patients were included if they had at least two claims
for diabetes medications and were continuously enrolled from
April 1, 2002 to March 31, 2004. Retrospective pre-post cohort
design, descriptive and multivariate modeling analyses were 
conducted to compare medication utilization between the two
cohorts. RESULTS: A total of 118 patients (37 in the interven-
tion and 81 in the comparison) were identiﬁed. There were no
signiﬁcant differences between the two cohorts in medication
possession ratio (MPR), pharmacy costs, and the number of 
prescriptions of diabetes drugs, ACE inhibitors, and needles at
baseline. During the 12-month post period, patients in the inter-
vention were more likely to have a prescription for test strips
(OR = 144.9, p < 0.0001) and needles (OR = 11.7, p < 0.0001).
Compared to the baseline period, patients with pharmacist inter-
vention had signiﬁcantly more prescriptions for test strips (0.68
vs. 5.32), diabetes medications (6.24 vs. 11.41), needles (1.27 vs.
4.24) and ACE inhibitors (1.68 vs. 3.03), a higher MPR with
diabetes drugs (0.67 vs. 0.96) and higher pharmacy costs ($689.9
vs. $1617.8), whereas patients in the comparison had no signif-
icant differences. CONCLUSIONS: APhA Diabetes Care Project
signiﬁcantly increased patients?adherence to therapy and uti-
lization for test strips, needles, diabetes medications and ACE
inhibitors. The increased adherence to therapy may offer both
clinical and cost beneﬁts to patients. (Acknowledgments: 
American Pharmacists Association; The Manitowoc Health Care
Coalition; Don F. Jabas Associates.)
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OBJECTIVE: To investigate the effects of a disease manage-
ment program on diabetic adults in a Medicaid population.
METHODS: This study was a retrospective database analysis of
diabetes-related costs and utilization and of overall costs. A pre-
post design with a concurrent control group was employed. To
ensure appropriate comparability, the study group and control
group were matched using propensity scoring techniques. Data
available for analysis spanned from July, 2000 to May, 2004,
while rolling enrollment period for the disease management
program occurred between October, 2002 and July, 2003.
RESULTS: From a potential pool of 2921 diabetics that were
identiﬁed within a Medicaid program, a study population of 388
was initially assessed for eligibility within counties that were 
targeted to implement the disease management program. After
applying exclusion criteria, 122 diabetics began enrollment
within the program. Ultimately, 32 diabetics completed the 12
month disease management program. Results indicated that
mean monthly diabetes-related medical costs per patient were
$190 in the pre-period and $225 in the post-period. Mean
monthly total medical costs per patient were $930 in the pre-
period and $939 in the post-period. Mean monthly pharmacy
costs per patient were $378 in the pre-period and $473 in the
post-period. Further multivariate analysis adjusted for demo-
graphic characteristics, initial utilization, and chronic disease
score. CONCLUSIONS: Higher costs in the post-period may be
associated with increased levels of care motivated by participa-
tion in the program. For a disease such as diabetes, the positive
long-term effects due to better care may not be apparent in the
short period of time during which the study data was gathered.
A longer-term analysis is warranted. In addition, a small pro-
portion of patients (8.2%) completed the full 12-month diabetes
